N6-Benzoyl-2'-O-(2-methoxyethyl)adenosine

Cat. No.: HY-23790: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

N6-Benzoyl-2'-O-(2-methoxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

Para uso exclusivo en investigación. No vendemos a pacientes.

N6-Benzoyl-2'-O-(2-methoxyethyl)adenosine Estructura química

No. CAS : 333335-93-6

Tamaño	Stock	Cantidad
10 mg	Obtener un presupuesto 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
25 mg	Obtener un presupuesto 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 mg	Obtener un presupuesto 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 mg	Obtener un presupuesto 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
200 mg	Obtener un presupuesto
500 mg	Obtener un presupuesto

Synthetic products have potential research and development risk.

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Peso molecular

429.43

Fòrmula

C₂₀H₂₃N₅O₆

No. CAS

333335-93-6

Appearance

Solid

Color

White to off-white

SMILES

O[C@H]1[C@@H](OCCOC)[C@H](N(C=N2)C3=C2C(NC(C4=CC=CC=C4)=O)=NC=N3)O[C@@H]1CO

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Pureza y Documentación

Instrucciones de manejo (2659 KB)

Referencias

[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. [Content Brief]